News
A Hawaiian woman, 37, was diagnosed with a rare instance of three overlapping neurological conditions caused by the body's ...
The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...
Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...
AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...
Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.
Gefurulimab met all primary and secondary endpoints in the Phase III PREVAIL trial in patients with gMG, run by pharma giant AstraZeneca.
Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.
Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...
Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...
AstraZeneca (AZN) stock is in focus as the company's experimental drug gefurulimab for generalized myasthenia gravis hits ...
The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...
AstraZeneca announced on Thursday that its investigational treatment ‘gefurulimab’ achieved statistically significant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results